Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel: Accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer

Applied Health Economics and Health Policy

Volumn 10, Issue 2, 2012, Pages 87-97

  Shavit, Oren ^a   Raz, Raanan ^b   Stein, Michal ^c   Chodick, Gabriel ^b,d   Schejter, Eduardo ^b   Ben David, Yehuda ^e   Cohen, Raanan ^c   Arbel, Daphna ^c   Shalev, Varda ^b,d  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MACCABI HEALTHCARE SERVICES   (Israel)

^c MSD Israel Co Ltd   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e HAEMEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COLPOSCOPY; CONDYLOMA ACUMINATUM; ECONOMIC EVALUATION; FEMALE; FEMALE GENITAL TRACT INFECTION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MORBIDITY; NONHUMAN; PAPANICOLAOU TEST; PRECANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CONDYLOMATA ACUMINATA; COST OF ILLNESS; DATABASES, FACTUAL; FEMALE; HUMANS; ISRAEL; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84857474169     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11594780-000000000-00000     Document Type: Article

References (40)

1. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70 (9): 1079-98
2. de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324 (1): 17-27 (Pubitemid 38737395)
3. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61 (6 Suppl. 1): S3-14 (Pubitemid 43880137)
4. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24 Suppl. 3: S3/11-25
5. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 Suppl. 3: S3/35-41
6. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 2004; 193 (1): 35-44 (Pubitemid 40585304)
7. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl. 10: K1-16
8. Wright Jr TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007; 11 (4): 223-39
9. Wright Jr TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11 (4): 201-22
10. Mortensen GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Public Health 2010; 10: 113
11. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008; 84 (3): 161-6 (Pubitemid 351871484)
12. Mortensen GL. Long-term quality of life effects of genital warts: a follow-up study. Dan Med Bull 2010; 57 (4): A4140
13. Insinga RP, Glass AG, Myers ER, et al. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007; 27 (4): 414-22 (Pubitemid 47106938)
14. Annemans L, Remy V, Oyee J, et al. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27 (3): 231-45
15. Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009; 36 (8): 515-21
16. Szarewski A. HPV vaccine: Cervarix. Expert Opin Biol Ther 2010; 10 (3): 477-87
17. Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006; 66 (9): 1263-71 (Pubitemid 44050440)
18. Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 2007; 25 (37-38): 6677-91 (Pubitemid 47337133)
19. Israel National Cancer Registry. Cancer incidence tables-Cervix Uteri, 2007 [online]. Available from URL: http:// www.health.gov.il/download/sartan/ 2007/cer-ut2007.pdf [Accessed 2010 Sep 1]
20. Menczer J. The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved? Isr Med Assoc J 2003; 5 (2): 120-3 (Pubitemid 36372185)
21. Sadan O, Schejter E, Ginath S, et al. Premalignant lesions of the uterine cervix in a large cohort of Israeli Jewish women. Arch Gynecol Obstet 2004; 269 (3): 188-91 (Pubitemid 38374706)
22. Menczer J. The human papillomavirus vaccine and its relevance in Israel. Isr Med Assoc J 2007; 9 (7): 546-9 (Pubitemid 47201673)
23. Israel National Cancer Registry. Cancer in Israel: trends in incidence and mortality 1982-2002 and selected updated data, 2004 [online]. Available from URL: http://www. health.gov.il/Download/pages/cancer290109.pdf [Accessed 2010 Sep 1]
24. Israel Central Bureau of Statistics. Statistical abstract of Israel 2005 [online]. Available from URL: http://www. cbs.gov.il/reader/shnaton/templ- shnaton.html?num-tab=st02-10x&CYear=2005 [Accessed 2010 Sep 1]
25. World Health Organisation. Cervical cancer, human papillomavirus (HPV), and HPV vaccines. Key points for policymakers and health professionals [online]. Available from URL: http://www.rho.org/files/WHO-PATH-UNFPA-cxca- key-points.pdf [Accessed 2010 Sep 1]
26. Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007; 18 (8): 1423-5 (Pubitemid 47305020)
27. Chodick G, Heymann AD, Wood F, et al. The direct medical cost of diabetes in Israel. Eur JHealth Econ 2005; 6 (2): 166-71 (Pubitemid 40905015)
28. Shalev V, Chodick G, Heymann AD. Format change of a laboratory test order form affects physician behavior. Int J Med Inform 2009; 78 (10): 639-44
29. Menczer J, Kogan L, Schejter E, et al. A population-based study of selected demographic characteristics of Israeli- Jewish women with cervical squamous cell carcinoma. Arch Gynecol Obstet 2011; 283 (3): 629-33
30. Israel Ministry of Health. Health Services tariff, 2010 [online]. Available from URL: http://www.health.gov.il/pages/ default.asp?maincat= 1&catId=111&PageId=827 [Accessed 2010 Jun 1]
31. Israel Ministry of Health. Israeli Health Insurance Law, 1994 [online]. Available from URL: http://www.health.gov. il/forms/forms.asp?category-id= 36&Element-Type-id=6 [Accessed 2010 May 31]
32. National Insurance Institute of Israel. Sick Funds Membership, April 2010 [online]. Available from URL: http://www.btl.gov.il/Mediniyut/Situation/ haveruth/Documents/ capitatia042010.pdf [Accessed 2010 May 31]
33. Israel Central Bureau of Statistics. Statistical abstract of Israel, 2009 [online]. Available from URL: http://www.cbs.gov.il/shnaton60/st02-19.pdf [Accessed 2010 Jun 1]
34. Israel Ministry of Health. Guidelines for the submission of a request to include a pharmaceutical product in the national list of health services, 2011 [online]. Available from URL: http://www.health.gov.il/pages/default.asp? maincat=11&catId=291&pageid=2133 [Accessed 2011 Jul 1]
35. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br Med J 2009; 339: b3884
36. Israel Central Bureau of Statistics. National expenditure on Health, 2011 [online]. Available from URL: http://www.cbs.gov.il/hodaot2010n/08-10-201e.pdf [Accessed 2011 Apr 1]
37. Henk HJ, Insinga RP, Singhal PK, et al. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010; 14 (1): 29-36
38. Israel Ministry of Health. Israel national cancer registry, 2002 [online]. Available from URL: http://www.health.gov. il/pages/default.asp? PageId=688&catId=56&maincat=22 [Accessed 2008 Sep 1]
39. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359 (8): 821-32
40. Center for the Evaluation of Value and Risk in Health. CEA Registry, 2010 [online]. Available from URL: https://re search.tufts-nemc.org/cear/Default. aspx 2010; [Accessed 2010 Aug 1]